Citation index
Sven Seiwerth, MD, PhD
University of Zagreb School of Medicine
Pathologist at the University of Zagreb whose research has included histopathological and preclinical evaluation of BPC-157 effects on tissue regeneration and wound healing in animal models.
Public profiles
Cited on Peptides Research Hub
- BPC-157: preclinical research overview and regulatory status
BPC-157 is a pentadecapeptide researched primarily in rodent models for potential effects on tendon, gastric mucosa, and other tissues. No regulatory agency has approved it for any therapeutic use. This page summarises preclinical findings, proposed mechanisms, the known limits of the evidence, and the research-only regulatory status in all covered jurisdictions.
- BPC-157: proposed mechanisms of action from preclinical studies
BPC-157
BPC-157 has been proposed to exert effects through nitric oxide synthesis modulation, VEGFR2-mediated angiogenesis, growth factor expression, and tendon fibroblast outgrowth. This article reviews the preclinical basis for each proposal and its current evidentiary limitations.
- BPC-157 half-life and pharmacokinetics: what the evidence does and does not show
BPC-157
Human pharmacokinetic data for BPC-157 do not exist in the peer-reviewed literature. Rat IV studies suggest a very short half-life (minutes to roughly 30 minutes), but species differences, route of administration, and assay limitations mean those figures cannot be extrapolated to humans.
- BPC-157 safety profile: the limits of current knowledge
BPC-157
BPC-157 has no approved use in any jurisdiction. Human safety data are absent. Rodent acute and subchronic toxicity studies suggest a wide margin, but species-specific metabolism, immunogenicity, and long-term effects in humans are unknown. This article details what is and is not known.